Beam Therapeutics (BEAM) Total Non-Current Liabilities (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Total Non-Current Liabilities data on file, last reported at $310.9 million in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 7.86% year-over-year to $310.9 million in Q1 2026; TTM through Mar 2026 was $310.9 million, a 7.86% decrease from a year earlier, with the FY2025 full-year figure at $242.6 million, down 34.27% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $310.9 million, up from $242.6 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for BEAM reached as high as $635.5 million in Q3 2022 and fell as low as $242.6 million in Q4 2025.
• Historically, Total Non-Current Liabilities has averaged $454.0 million across 5 years, with a median of $443.4 million in 2024.
• Across the five-year window, Total Non-Current Liabilities surged 127.57% in 2022 and tumbled 34.27% in 2025, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $606.9 million in 2022, then dropped by 21.62% to $475.7 million in 2023, then slipped by 22.39% to $369.1 million in 2024, then tumbled by 34.27% to $242.6 million in 2025, then gained by 28.13% to $310.9 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $310.9 million in Q1 2026, $242.6 million in Q4 2025, and $344.8 million in Q3 2025.